Kufril LS Drop is a combination oral solution containing Ambroxol (7.5 mg/ml), Levosalbutamol (0.25 mg/ml), and Guaifenesin (12.5 mg/ml), formulated to provide symptomatic relief in respiratory conditions characterized by productive cough and bronchospasm. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency. Levosalbutamol, a selective β2-adrenergic receptor agonist, exerts bronchodilator effects by relaxing bronchial smooth muscle, which helps alleviate bronchospasm and improve airflow. Guaifenesin serves as an expectorant, promoting the hydration of respiratory tract secretions and enhancing mucociliary clearance. This combination is indicated for the management of acute and chronic bronchitis, asthma exacerbations, and other obstructive airway diseases where mucus hypersecretion and bronchoconstriction coexist. Kufril LS Drop should be administered as per the prescribed dosage, taking into account patient age and clinical condition. Caution is advised in patients with hypersensitivity to any component, cardiovascular disorders, or hyperthyroidism. Adverse effects may include gastrointestinal disturbances, tremors, or allergic reactions. Consultation with a healthcare professional is recommended before use to ensure appropriate therapy and monitoring.